2. Membrane Transporter/Ion Channel
  3. ATP Synthase
  4. Cyclocreatine

Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Cyclocreatine

Cyclocreatine 화학구조

CAS No. : 35404-50-3

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in Water 해외재고보유
Solid
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

Other Forms of Cyclocreatine:

Cyclocreatine Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Cyclocreatine

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer[1][2][3][4][5].

In Vitro

Cyclocreatine (5 or 10 mM, 24 or 40 h) improves extracellular acidification rate (ECAR) which is accompanied by less Autophagy, increases mTOR signaling and cell viability in bone marrow-derived macrophages[2].
Cyclocreatine (0-50 mM, 24 h) suppresses creatine metabolism, proliferation and creatine uptake in prostate cancer cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cyclocreatine Related Antibodies

Western Blot Analysis[2]

Cell Line: Bone marrow-derived macrophages
Concentration: 5 or 10 mM
Incubation Time: incubation for 24 or 40 h
Result: Increased mTOR signaling and cell viability in bone marrow-derived macrophages.

Cell Proliferation Assay[3]

Cell Line: Murine and human prostate cancer cells
Concentration: 0-50 mmol/L
Incubation Time: 24 h
Result: Impaired in vitro proliferation of both human and murine prostate cancer cells
In Vivo

Cyclocreatine (500 mg/kg, i.v., a single dose for 60 min) restores heart contractile function and shows markedly less myocardial cell injury when compared to the control (saline) group in the acute myocardial infarction (AMI) intact dog model[1].
Cyclocreatine (0.28 mg/g, drink, supplementation daily from 10-week to 8 months) rescues microgliosis and clustering and moderates neurite dystrophy in TREM2−/− 5XFAD mice[2].
Cyclocreatine (40 mg, gavage, daily for 1 month) significantly reduces liver metastatic burden and affects prostate cancer progression in a model of liver metastasis of mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: AMI-intact dog model[1]
Dosage: 500 mg/kg
Administration: i.v., a single dose for 60 min
Result: Preserved 85% of pre-ischemic ATP level (loss of only 15%) and 97% of the CrP (loss of 3%) during ischemia, as well as immediately restored over 80% of contractile function during the 2 h of reperfusion in AMI-intact dog model.
Animal Model: 5XFAD and TREM2−/− 5XFAD mice
Dosage: 0.28 mg/g
Administration: Drinking water supplementation with cyclocreatine daily from 10-week to 8 months
Result: Improved microglial metabolism and the protective response to Aβ plaques in TREM2-deficient 5XFAD mice.
분자량

143.15

화학식

C5H9N3O2
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=C(O)CN1CCNC1=N
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

용액&용해도
In Vitro: 

1M HCl : 100 mg/mL (698.57 mM; ultrasonic and adjust pH to 2 with HCl)

H2O : 5 mg/mL (34.93 mM; ultrasonic and warming and heat to 60°C)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.9857 mL 34.9284 mL 69.8568 mL
5 mM 1.3971 mL 6.9857 mL 13.9714 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 10 mg/mL (69.86 mM); Clear solution; Need ultrasonic and warming

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
순도&문서

Purity: 99.78%

SDS (394 KB)

COA (248 KB) HNMR (223 KB) RP-HPLC (245 KB) MS (205 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / 1M HCl 1 mM 6.9857 mL 34.9284 mL 69.8568 mL 174.6420 mL
5 mM 1.3971 mL 6.9857 mL 13.9714 mL 34.9284 mL
10 mM 0.6986 mL 3.4928 mL 6.9857 mL 17.4642 mL
15 mM 0.4657 mL 2.3286 mL 4.6571 mL 11.6428 mL
20 mM 0.3493 mL 1.7464 mL 3.4928 mL 8.7321 mL
25 mM 0.2794 mL 1.3971 mL 2.7943 mL 6.9857 mL
30 mM 0.2329 mL 1.1643 mL 2.3286 mL 5.8214 mL
1M HCl 40 mM 0.1746 mL 0.8732 mL 1.7464 mL 4.3660 mL
50 mM 0.1397 mL 0.6986 mL 1.3971 mL 3.4928 mL
60 mM 0.1164 mL 0.5821 mL 1.1643 mL 2.9107 mL
80 mM 0.0873 mL 0.4366 mL 0.8732 mL 2.1830 mL
100 mM 0.0699 mL 0.3493 mL 0.6986 mL 1.7464 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cyclocreatine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cyclocreatine35404-50-3ATP Synthasecreatine analoguebrain-penetrantphosphorylateddephosphorylatedcardiac recoverycreatine metabolismischemic heart diseasecardiovascular diseasesAlzheimer’s diseaseprostate cancerInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Cyclocreatine
Cat. No.:
HY-W017540
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.